Compare PLUG & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLUG | ZYME |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1999 | 2022 |
| Metric | PLUG | ZYME |
|---|---|---|
| Price | $1.04 | $26.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 14 |
| Target Price | $3.12 | ★ $43.29 |
| AVG Volume (30 Days) | ★ 45.0M | 1.0M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.01 | 33.33 |
| EPS | N/A | ★ 1.08 |
| Revenue | ★ $709,919,000.00 | $105,965,000.00 |
| Revenue This Year | $15.76 | $220.24 |
| Revenue Next Year | $18.46 | $6.44 |
| P/E Ratio | ★ N/A | $23.11 |
| Revenue Growth | 12.90 | ★ 38.87 |
| 52 Week Low | $1.00 | $21.52 |
| 52 Week High | $4.33 | $31.97 |
| Indicator | PLUG | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 27.51 | 46.04 |
| Support Level | N/A | $22.28 |
| Resistance Level | $2.50 | $27.40 |
| Average True Range (ATR) | 0.11 | 1.54 |
| MACD | -0.02 | -0.45 |
| Stochastic Oscillator | 5.10 | 28.27 |
Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.